Tests a higher-dose radiation plan for lung and chest tumours
Compares two radiation plans, one sparing the esophagus, in adults with lung cancer.
Plain-language title generated from the registry record
Registry title: An Evaluation of Dose-escalation for Intrathoracic Tumours
Key facts
- Where
- Kelowna, London, Saint John, and Waterloo, CanadaSee the 4 sites
Where in Canada
- British Columbia Cancer Agency Center for the Southern InteriorKelowna, CanadaTaking people
- London Health Sciences Center Research Institute (Formerly Lawson Research Institute)London, CanadaTaking people
- Horizon Health New BrunswickSaint John, CanadaTaking people
- Waterloo Regional Health NetworkWaterloo, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Chris Goodman
- Trial code
- NCT06794125
- Record updated
- 14 September 2026
- Original description
This is a pragmatic trial with patients randomized between standard of care palliative thoracic radiation therapy (RT) vs. hypofractionated, dose-escalated, esophageal-sparing (HD-ES) intensity modulated radiation therapy (IMRT).Read full original descriptionShow less
A Phase II/III Randomized Evaluation of Dose-escalation With Esophageal-sparing for Palliation of Intrathoracic Tumours (PREVENT)
This is a pragmatic trial with patients randomized between standard of care palliative thoracic radiation therapy (RT) vs. hypofractionated, dose-escalated, esophageal-sparing (HD-ES) intensity modulated radiation therapy (IMRT).
The investigators hypothesize that the use of advanced radiation planning techniques to optimize dose to esophagus will permit the safe delivery of a modestly dose-escalated five-fraction course of palliative radiation to intrathoracic malignancies. This approach aims to deliver higher biologically effective doses while improving toxicity when compared to conventional approaches with the goal of prolonging high-quality overall survival.
Inclusion: Intrathoracic tumour requiring palliative radiation, either for palliation of symptoms or prevention of progression that is expected to cause symptoms in the next 6 months (in the judgement of the enrolling investigator); Willingness and ability to provide informed consent; Eastern Cooperative Oncology Group performance status 0-3; Age 18 years or older; Prior or planned systemic treatment (chemotherapy, immunotherapy, targeted agents) is permissible at the discretion of the treating medical oncologist; Concurrent palliative radiotherapy to other metastatic sites is permissible at the discretion of the treating radiation oncologist; Life expectancy greater than 3 months.
Exclusion: Prior thoracic radiotherapy which, in the opinion of the treating of radiation oncologist, precludes the delivery of further thoracic radiotherapy. If there has been prior thoracic radiotherapy, a composite of all RT plans must be created, and the dose constraints herein must still be met. An allowance for 10 percent repair is permitted if at least 12 months have passed between the prior radiotherapy and the trial protocol specified radiotherapy; Inability to attend the full course of radiotherapy or planned follow-up visits; Serious medical comorbidities which, in the opinion of the treating radiation oncologist, preclude the delivery of radiotherapy. This includes interstitial lung disease; Pregnant or lactating women.